Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Biotech
STAT+
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

This biotech just bought three failed drugs. Here’s why

  • Kate Sheridan

By Kate Sheridan Feb. 5, 2020

Reprints
Pink brain psychology
Adobe

Biopharma companies don’t usually buy experimental drugs that don’t work.

But that’s exactly what CODA Biotherapeutics has done.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

Nobel Prize in medicine awarded for research into the…
Nobel Prize in medicine awarded for research into the evolutionary history of humankind
Who will get the call from Stockholm? It’s time…
Who will get the call from Stockholm? It’s time for STAT’s 2022 Nobel Prize predictions
Push to double up on Covid booster and flu…
Push to double up on Covid booster and flu shot may have a downside, experts caution
Pharmalittle: U.S. Supreme Court asks solicitor general for views…
Pharmalittle: U.S. Supreme Court asks solicitor general for views on ‘skinny label’ case; Express Scripts and…
CAR-T therapy doesn’t work in all cancer cases. Scientists…
CAR-T therapy doesn’t work in all cancer cases. Scientists are starting to figure out why
At Verily, a growing line of business builds on…
At Verily, a growing line of business builds on a revolving door to the FDA

Recommended Stories